Trials
2 active
3 in total · 2 in the EU
What this is
- How it works
- A short strand of RNA that switches off one gene, so the body makes less of one protein.-siran: small interfering RNA WHO name stem
- Tested for
- Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN, Transthyretin Amyloidosis With Cardiomyopathy
- Main trialPhase 3
- “The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed * Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels”In the company’s words, NCT07223203 on ClinicalTrials.gov
- Other names
- ALN-TTRSC04
Other drugs for Transthyretin Amyloidosis With Cardiomyopathy
- SotagliflozinLexicon Pharmaceuticals · Phase 3
- HRS-1893Hengrui · Phase 3
- NTLA-2001Intellia Therapeutics · Phase 3
- VutrisiranAlnylam · Phase 3
- BHB-1893Braveheart Bio, Inc. · Phase 3
- AficamtenCytokinetics · Phase 2/3
Coming up2
- 27 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- 28 May 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 27 Dec 2027 | TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy | |
| Phase 3Recruiting | 28 May 2030 | TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | |
| Phase 1Completed | 30 Sep 2025 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026